RECENT NEWS: SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” SymposiumHighlights

SEED Therapeutics’ Mission

 

To break through the scientific barriers to discovering Molecular Glues for effective therapy and cures for the world’s most debilitating diseases and disorders.

Collaborating with an unparalleled team of world-leading experts in the Ubiquitin Proteasome System and the field of Targeted Protein Degradation.  SEED Therapeutics is advancing its groundbreaking Molecular Glues discovery platform for the treatment of multiple indications, including cancer, neurodegradation, and infectious diseases.

DRUG DISCOVERY

About Seed Therapeutics

SEED Therapeutics: A focus on Molecular Glues

SEED Therapeutics is a global research company uniquely focused on harnessing and engineering molecules that use Molecular Glues to attack protein targets previously believed to be ”undruggable.”

Natures Protein Recycling Mechanism
Molecular Glues
Scientific Challenges of Molecular Glue Discovery
SEED Leadership Team

PIPELINE

pipeline
Seed Therapeutics Pipeline Chart

THE TEAM

leadership
Click below to learn more about SEED Therapeutics’ leadership 
our leadership

LEADERSHIP TEAM

board of directors

BOARD OF DIRECTORS

NEWSROOM

communications

Press Releases

 

Events

 

“Targeted Protein Degradation Think Tank” Symposium

August 10, 2020
BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Eli Lilly
Continue reading >

August 7, 2020
BeyondSpring Creates Subsidiary, Seed Therapeutics, to Focus on Protein Degradation Platform
Continue reading >

PARTNERS

leadership team
Eli Lilly and Company

CAREERS

careers

Make a difference in improving human health